Could dropping aspirin after a heart attack save hearts?

NCT ID NCT05986968

Ongoing Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial asks whether giving only ticagrelor (a blood thinner) after a heart attack, instead of the usual ticagrelor plus aspirin, is just as safe and might reduce bleeding and heart muscle damage. About 200 people who had a type of heart attack called STEMI and underwent a stent procedure will be randomly assigned to one of the two treatments for 12 months. Researchers will compare heart events, bleeding, and heart damage seen on MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ticagrelor (antiplatelet drug) used alone, compared to ticagrelor plus aspirin
What this could lead to: If successful, this could lead to a safer post-heart-attack treatment that reduces bleeding risk and heart muscle damage while preventing further heart events.
What could go wrong: This is a mid-sized trial, and results may not apply to all patients. There is a risk that omitting aspirin could increase the chance of blood clots or heart attacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST ELEVATION MYOCARDIAL INFARCTION

Contacts and locations

Locations

Amsterdam UMC

Amsterdam, Netherlands
Medisch Spectrum Twente

Enschede, Netherlands
Noordwest Ziekenhuisgroep Alkmaar

Alkmaar, Netherlands
Radboudumc

Nijmegen, Netherlands
Rijnstate

Arnhem, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.